News & Updates

In the treatment of patients with relapsed or persistent ovarian clear cell carcinoma, the combination of sintilimab plus bevacizumab has demonstrated promising antitumour activity and manageable safety in the phase II INOVA trial.

The investigational L-type amino acid transporter 1 inhibitor nanvuranlat has an acceptable safety profile and is associated with prolonged progression-free survival (PFS) in patients with advanced and refractory biliary tract cancer when used in later-line treatment settings, according to the results of a phase II study.

In a comparative analysis presented at WONCA 2024, individuals who are being treated with pitavastatin appear to be at greater risk of developing new-onset diabetes as opposed to those receiving rosuvastatin.

Treatment with a single dose of tamsulosin prior to minimally invasive hysterectomy for benign conditions does not shorten postoperative time to void or time to discharge, as reported in a study.

Monthly dosing of the anti-PCSK9 small binding protein lerodalcibep appears to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular disease (CVD) or at high risk of atherosclerotic CVD who are unable to achieve target LDL-C levels while receiving maximal tolerated statins alone, according to the phase III LIBERATE-HR trial.

A registry-based cohort study presented at ERS 2024 demonstrates a relationship between antibiotic exposure in early life and the development of immune-mediated diseases (IMDs) in childhood and young adulthood.

Cannabinoids for medical purposes in children and adolescents have been linked to increased risk of adverse events (AEs), according to the results of a meta-analysis.